Join
Live feed
·
PRReleasevia Quantisnow
Biohaven Ltd. logo

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

ByQuantisnow·Wall Street's wire, on your screen.
BHVN· Biohaven Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BHVN (Biohaven Ltd.) and more on Quantisnow.